[Press release] Mirum Pharmaceuticals announces primary endpoint met in Phase 3 AZURE-1 study of brelovitug in chronic hepatitis delta virus
Mirum Pharmaceuticals announced that its investigational drug brelovitug met the primary endpoint in the Phase 3 AZURE-1 study for chronic hepatitis delta virus (HDV). The company also reported positive 48-week data from the Phase 2b portion of the study, showing deepened viral suppression and increased rates of ALT normalization. This study is one of two pivotal Phase 3 trials intended to support Mirum’s U.S. registration package for brelovitug.
(MIRM) as a Liquidity Pulse for Institutional Tactics
This article analyzes Mirum Pharmaceuticals Inc. (NASDAQ: MIRM) using AI models to provide insights for institutional trading strategies. It highlights weak near- and mid-term sentiment challenging a strong long-term outlook, offering specific position trading, momentum breakout, and risk hedging strategies. The analysis also includes multi-timeframe signal data with support and resistance levels.
Mirum Pharmaceuticals' Brevlovitug Hits Phase III Endpoint in Hepatitis Delta Study
Mirum Pharmaceuticals announced positive Phase III results for brelovitug in treating chronic hepatitis delta, with 56% of patients achieving the primary endpoint of virologic response and ALT normalization. The company anticipates filing a biologics license application in the first half of next year and projects peak U.S. sales of at least $1 billion for brelovitug. Additionally, Mirum plans to launch its newly FDA-approved FOP treatment, Atebrioz, in October, with revenue expected to commence in Q1 2027.
Citi Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $160
Citi has reiterated its Buy rating for Mirum Pharmaceuticals (MIRM.US) and maintained its target price at $160. This continued positive outlook suggests the firm believes Mirum Pharmaceuticals' stock will perform well, reinforcing confidence in the company's financial prospects and market position.
Mirum Pharmaceuticals Is Maintained at Outperform by Baird
Baird has maintained its Outperform rating on Mirum Pharmaceuticals, signaling continued confidence in the company's prospects. This reiteration suggests that the analyst firm believes Mirum Pharmaceuticals' stock will continue to perform well relative to the broader market. The report likely underscores positive outlooks on the company's strategic direction, financial health, or product pipeline.
What Could Mirum Pharmaceuticals (MIRM) Approval And Phase 3 Win Mean Now?
Mirum Pharmaceuticals (MIRM) recently received US FDA approval for Atebrioz (zilurgisertib) to treat fibrodysplasia ossificans progressiva and announced positive Phase 3 data for brelovitug in chronic hepatitis delta virus. These developments are significant for the company's focus on rare and orphan diseases, aiming for revenue diversification beyond Livmarli. Investors are now keen to see the real-world uptake of Atebrioz and whether Mirum proceeds with regulatory filings for brelovitug as planned, as these factors will shape the company's long-term growth and valuation.
EBITDA of Mirum Pharmaceuticals, Inc. – HAN:08D
This article provides the EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) information for Mirum Pharmaceuticals, Inc. trading under the HAN:08D symbol on the Hannover Stock Exchange. The content appears to be a financial data snippet from a larger platform, indicating the value and change of EBITDA over a period. It highlights that the market was closed with no trades at the time of reporting.
Debt to equity ratio of Mirum Pharmaceuticals, Inc. – HAN:08D
This article displays the debt to equity ratio for Mirum Pharmaceuticals, Inc. (HAN:08D) on the TradingView platform. It provides financial data for the company traded on the Hannover Stock Exchange. The page indicates market is closed with no trades.
Mirum Pharmaceuticals, Inc. (MIRM) Discusses Topline Results from Phase III AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta - Slideshow (NASDAQ:MIRM)
Mirum Pharmaceuticals, Inc. (MIRM) discussed the topline results from its Phase III AZURE-1 study of Brelovitug for chronic Hepatitis Delta. The company published a slide deck in conjunction with this event. This update comes from SA Transcripts, which manages the publication of earnings calls and other related financial transcripts.
Mirum Pharmaceuticals to Host Investor Call to Share Topline Results from the Phase 3 AZURE-1 Study of Brelovitug in Chronic Hepatitis Delta on September 28, 2026
Mirum Pharmaceuticals announced it will host an investor call on September 28, 2026, to present topline results from its Phase 3 AZURE-1 study of brelovitug for chronic hepatitis delta virus (HDV), alongside 48-week data from the Phase 2b portion of the study. The call will also discuss the company's broader pipeline and existing rare disease therapies.
Mirum Pharmaceuticals, Inc. Meets Primary Endpoint In Phase 3 AZURE-1 Study Of Brelovitug In Chronic Hepatitis Delta Virus
Mirum Pharmaceuticals announced that its investigational drug brelovitug met the primary endpoint in the Phase 3 AZURE-1 study for chronic hepatitis delta virus (HDV). The study showed that brelovitug achieved virologic response and ALT normalization in a significant percentage of patients at Week 24. Furthermore, 48-week data from the Phase 2b portion of the study demonstrated deepening viral suppression and a consistent safety profile.
MIRM5806400 Bond Profile: Coupon and Redemption
This article provides a detailed profile of the Mirum Pharmaceuticals, Inc. 4.0% 01-MAY-2029 bond (MIRM5806400). It covers key facts such as the issuer, issue and maturity dates, face value, and a description of Mirum Pharmaceuticals. The bond profile also includes information on interest payments, a coupon payout schedule, and redemption details.
Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva
Mirum Pharmaceuticals and Incyte have received U.S. FDA approval for Atebrioz™ (zilurgisertib) tablets for the treatment of Fibrodysplasia Ossificans Progressiva (FOP) in patients aged 12 and older. This once-daily oral ALK2 inhibitor is designed to reduce the volume of total new heterotopic ossification, a key symptom of FOP. Atebrioz is expected to be available in the U.S. in October through the Mirum Access Plus (MAP) patient support program, with ongoing development for younger pediatric patients.
Mirum Pharmaceuticals stock trades at USD 98.22 as targets reach USD 137.31
Mirum Pharmaceuticals (MIRM) stock closed at USD 98.22 on September 22, 2026, down 2.4%, with analysts setting a consensus price target of USD 137.31. The company reported revenue of USD 521.31 million and a market capitalization of USD 6.38 billion, despite negative net income and EPS. The gap between the current price and target reflects future earnings expectations rather than immediate profitability.
Mirum Pharmaceuticals Names Rob Myers Chief Medical Officer
Mirum Pharmaceuticals has appointed Rob Myers, MD, as its new Chief Medical Officer. Dr. Myers brings over two decades of experience in developing novel medicines, particularly as a hepatologist, and will lead Mirum's global medical and clinical development functions. His appointment is expected to support the rare disease company's growing commercial portfolio and late-stage pipeline, replacing Joanne Quan, MD, who is departing the company.
Mirum Pharmaceuticals (MIRM) CFO offloads shares after RSUs vest
Mirum Pharmaceuticals' CFO, Eric Bjerkholt, sold 9,943 shares of common stock at $98.37 per share to cover tax withholding obligations after 18,333 Restricted Stock Units (RSUs) vested on September 11, 2026. This transaction was reported in a Form 4 filing and was not executed under a Rule 10b5-1 trading plan. After the sale, Bjerkholt holds 44,745 direct shares of common stock, with zero RSUs remaining.
Mirum Pharma (MIRM) officer to sell shares to cover equity taxes
An officer at Mirum Pharmaceuticals (MIRM), Eric Bjerkholt, has filed a Rule 144 notice to sell up to 9,943 shares of common stock, valued at approximately $978,092.91. This sale is primarily intended to cover taxes associated with recently vested stock unit awards. The filing also disclosed previous sales by Bjerkholt totaling 11,001 shares over the past three months.
Citizens reiterates Mirum Pharmaceuticals stock rating at outperform By Investing.com
Citizens reiterated a Market Outperform rating and $137 price target for Mirum Pharmaceuticals (NASDAQ:MIRM) despite its drug zilurgisertib missing statistical significance in a pivotal trial for FOP, believing the data still supports approval. The firm forecasts $150 million in peak worldwide sales for zilurgisertib and highlights upcoming catalysts including data from brelovitug for HDV and Livmarli's Phase 3 EXPAND trial. Mirum also reported strong Q2 net product sales and raised its 2026 sales outlook, with other analysts maintaining positive ratings.
Precision Trading with Mirum Pharmaceuticals Inc. (MIRM) Risk Zones
This article provides a detailed stock analysis for Mirum Pharmaceuticals Inc. (NASDAQ: MIRM), indicating a neutral near and mid-term outlook with a potentially moderating long-term positive bias. It presents three distinct AI-generated trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—tailored for different risk profiles, along with multi-timeframe signal analysis, including support and resistance levels. The analysis highlights an elevated downside risk due to the absence of additional long-term support signals.
Mirum Pharmaceuticals Hires LMH Strategic Solutions
Mirum Pharmaceuticals Inc. has retained LMH Strategic Solutions LLC to represent its lobbying interests on Capitol Hill, specifically focusing on health policy. This engagement comes as Congress addresses the implications of the "One Big Beautiful Bill Act," which expanded orphan drug exemptions from Medicare price negotiation. Alanna Temme, founder of LMH Strategic Solutions, will lead the lobbying efforts for Mirum Pharmaceuticals.
Mirum Pharmaceuticals (MIRM) Short Interest & Short Float | Updated Sep 2026
This article provides an updated overview of Mirum Pharmaceuticals' (MIRM) short interest as of August 31, 2026. It details that 6.17 million shares, or 10.37% of the public float, are sold short, marking a 4.89% decrease from the previous report. The short interest ratio stands at 13.2 days to cover, indicating a high level of pessimism from short sellers.
Mirum Pharmaceuticals Appoints Dr. Rob Myers as Chief Medical Officer
Mirum Pharmaceuticals has announced the appointment of Dr. Rob Myers as Chief Medical Officer, effective September 21, 2026. Dr. Myers, a renowned hepatologist with over two decades of experience in drug development, will lead Mirum's global medical and clinical development functions. This appointment comes as Mirum anticipates growth in its commercial portfolio and further diversification of its late-stage pipeline.
Mirum Pharmaceuticals, Inc.'s (NASDAQ:MIRM) Profit Outlook
This article focuses on the profit outlook for Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), highlighting the company's financial performance and future projections. It likely discusses analyst expectations, revenue forecasts, and potential factors influencing profitability.
Mirum Pharmaceuticals SVP Howe Jolanda Disposes of 658 Shares at $100 Each (NASDAQ: MIRM)
Mirum Pharmaceuticals' SVP and Global Controller, Howe Jolanda, sold 658 shares of the company stock at $100 per share on September 2, 2026. After this transaction, Jolanda retains ownership of 616 shares of Mirum Pharmaceuticals (NASDAQ: MIRM). This insider sale provides insight into the executive's actions and remaining stake in the company for investors.
Mirum Pharmaceuticals global controller sells $65,800 in stock
Jolanda Howe, Senior Vice President and Global Controller at Mirum Pharmaceuticals, sold 658 shares of company stock for $65,800 on September 2, 2026, pursuant to a pre-arranged trading plan. This insider sale occurred while MIRM stock trades near $100.63, up 27% year-to-date, despite InvestingPro analysis suggesting it may be overvalued. The company recently reported strong Q2 net product sales and raised its 2026 sales outlook, though concerns about a delayed filing for volixibat impacted the stock.
Mirum CEO Christopher Peetz sells $2.96 million in shares
Mirum Pharmaceuticals CEO Christopher Peetz sold 30,000 shares of company stock for $2.96 million on September 1, 2026, following the exercise of stock options. The sales were conducted under a Rule 10b5-1 trading plan. Despite the company's strong revenue growth and positive analyst ratings, its stock is considered overvalued, and there are regulatory concerns regarding a key drug candidate.
Why Is Mirum Pharmaceuticals (MIRM) Up 6.9% Since Last Earnings Report?
Mirum Pharmaceuticals (MIRM) shares have risen 6.9% since its last earnings report, outperforming the S&P 500. The company reported a wider-than-expected loss for Q2 2026 but beat revenue estimates, driven by strong sales of Livmarli and bile acid products, leading to a raised revenue guidance for 2026.
Mirum Pharmaceuticals CEO Christopher Peetz Executes Stock Option and Sells Shares Under 10b5-1 Plan
Christopher Peetz, CEO of Mirum Pharmaceuticals (NASDAQ:MIRM), exercised a fully vested stock option for 30,000 shares and subsequently sold all these shares in two tranches on September 1, 2026. These transactions, executed under a Rule 10b5-1 trading plan, resulted in weighted average sale prices of $98.08 and $98.91 respectively. Post-transactions, Peetz directly holds 194,440 shares and indirectly 187,500 shares through The Peetz Family Trust, while retaining 58,487 employee stock options.
Mirum Pharmaceuticals SVP Jolanda Howe Sells 658 Shares via 10b5-1 Trading Plan
Jolanda Howe, SVP and Global Controller at Mirum Pharmaceuticals (NASDAQ: MIRM), sold 658 shares of company stock on September 2, 2026, at $100 per share. This transaction was conducted under a pre-established Rule 10b5-1 trading plan. After the sale, Howe directly holds 616 shares of Mirum Pharmaceuticals.
Five investor conferences are on Mirum’s September schedule
Mirum Pharmaceuticals (NASDAQ: MIRM) announced its participation in five investor conferences in September 2026, including events hosted by Cantor, Citi, H.C. Wainwright, Baird, and Morgan Stanley. The company will conduct fireside chats at several of these conferences, with live webcasts and archived replays available on its investor relations website. This engagement highlights Mirum's efforts to communicate with the investment community about its rare disease portfolio and pipeline.
Mirum Pharmaceuticals Inc (08D) Q3 2023 Earnings Report - Results, Call & Slides
Mirum Pharmaceuticals Inc (08D) reported its Q3 2023 earnings, surpassing analyst expectations. The company recorded an actual EPS of -€0.49 against a consensus of -€0.54 and actual revenue of €40.94M, beating the expected €33.11M. This represents a significant year-over-year revenue growth of 154.13%.
Citizens reiterates Mirum Pharmaceuticals stock rating on trial data
Citizens has reiterated a Market Outperform rating and a $137.00 price target for Mirum Pharmaceuticals (NASDAQ:MIRM) following positive interim AZURE-1 trial data for brelovitug, which is being developed for HDV. The firm believes the trial results substantially de-risked future readouts and that brelovitug has a competitive efficacy and a clean safety profile, projecting peak sales of approximately $675 million. Despite a recent stock pullback, Citizens anticipates positive AZURE-1 data will drive shares higher.
Mirum Pharmaceuticals (MIRM) Following Rare Disease Growth Narrative Looks Undervalued
Mirum Pharmaceuticals (MIRM) is considered undervalued despite a recent stock price pullback, with a narrative fair value estimate of $144.15 against a current close of $96.72. The company is gaining attention for its Volixibat candidate in liver cirrhosis therapies, and its rare disease portfolio is expected to drive sustained revenue growth due to an expanding patient population. However, the valuation carries risks related to potential underperformance of Livmarli or pressures on rare disease drug pricing.
H.C. Wainwright Maintains Mirum Pharmaceuticals(MIRM.US) With Buy Rating, Maintains Target Price $140
H.C. Wainwright has reiterated its Buy rating on Mirum Pharmaceuticals (MIRM.US) and maintained its target price at $140. This indicates the firm's continued confidence in the pharmaceutical company's stock performance.
MIRM5806400 Bond Profile — Key Metrics
This article provides key metrics for the Mirum Pharmaceuticals, Inc. bond (MIRM5806400), detailing its 4.0% coupon rate and a maturity date of May 1, 2029. It outlines the bond's issue date, outstanding amount, face value, and minimum denomination. The company, Mirum Pharmaceuticals, is introduced as a biopharmaceutical firm focused on therapies for liver diseases.
H.C. Wainwright reiterates Mirum Pharmaceuticals stock rating at buy
H.C. Wainwright has reiterated a Buy rating and a $140.00 price target for Mirum Pharmaceuticals (NASDAQ:MIRM). The company's stock has seen a 53% gain over the past year, though InvestingPro analysis suggests it may be overvalued relative to its Fair Value despite recent earnings revisions. The article also mentions the FDA approval of Regeneron Pharmaceuticals' garetosmab for fibrodysplasia ossificans progressiva, a condition for which Mirum Pharmaceuticals' products are not directly related.
Lisanti Capital Growth LLC Takes Position in Mirum Pharmaceuticals, Inc. $MIRM
Lisanti Capital Growth LLC has acquired 63,295 shares of Mirum Pharmaceuticals (NASDAQ:MIRM) worth $7.41 million, making it their eighth-largest portfolio holding. Other institutional investors like BlackRock, Janus Henderson, State Street, and Wellington Management have also increased their positions. Despite missing quarterly EPS estimates and significant insider selling, analysts maintain a "Moderate Buy" rating with a consensus price target of $137.33.
Mirum Pharmaceuticals(MIRM.US) Officer Sells US$4 Million in Common Stock
A Mirum Pharmaceuticals officer recently sold common stock valued at approximately $4 million. This transaction indicates a significant insider sale at the company.
Mirum Pharmaceuticals (MIRM) SVP exercises 40k options, sells shares
Jolanda Howe, SVP, Global Controller at Mirum Pharmaceuticals (MIRM), exercised 40,000 employee stock options at $6.27 per share and subsequently sold all 40,000 common shares at $100.00 per share on August 18, 2026. This transaction resulted in an approximate pre-tax spread of $3.75 million. Following the transactions, Howe's stock option position was reduced to zero, while her direct common stock holdings stand at 1,274 shares.
Jolanda Howe Sells 40,000 Shares of Mirum Pharmaceuticals (NASDAQ:MIRM) Stock
Jolanda Howe, SVP of Mirum Pharmaceuticals (NASDAQ:MIRM), sold 40,000 shares of the company's stock for $4 million on August 18th, reducing her stake by 96.91% to 1,274 shares. This sale follows several other transactions since June. The company's stock trades at $102.24 with a $6.64 billion market cap, and analysts maintain a "Moderate Buy" rating with an average price target of $137.33 despite missing recent EPS estimates.
Mirum Pharmaceuticals SVP, Global Controller Sold Shares Worth Over $4M
Mirum Pharmaceuticals' SVP, Global Controller, Howe Jolanda, sold 40,000 shares of Common Stock for a total of $4,000,000 at $100.00 per share. Following this transaction, Jolanda directly owns 1,274 shares. This information is based on an SEC Form 4 filing and highlights an insider stock sale.
Mirum Pharma (NASDAQ: MIRM) officer lines up $4M share sale
Jolanda Marie Howe, an officer at Mirum Pharmaceuticals, Inc. (NASDAQ: MIRM), has filed a Form 144 to sell 40,000 common shares valued at $4,000,000.00 on August 18, 2026, following a stock option exercise. The sale will be executed through Morgan Stanley Smith Barney. The filing also reports her previous sales of Mirum common stock in June, July, and August 2026.
TimesSquare Capital Management LLC Invests $43 Million in Mirum Pharmaceuticals, Inc. $MIRM
TimesSquare Capital Management LLC has invested $43 million in Mirum Pharmaceuticals, acquiring 367,281 shares. This move is part of broader institutional interest, even as some analysts have adjusted their ratings and price targets. Mirum Pharmaceuticals, a company focused on rare cholestatic liver diseases, reported strong revenue growth but wider-than-expected losses in its latest quarter, and insiders have sold approximately $9.8 million in stock.
Rice Hall James & Associates LLC Acquires New Position in Mirum Pharmaceuticals, Inc. $MIRM
Rice Hall James & Associates LLC has acquired a new position in Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM), purchasing 110,673 shares valued at approximately $13.0 million. This comes as Mirum Pharmaceuticals reported a 37.9% increase in quarterly revenue year-over-year, reaching $176.24 million, although it also posted a larger-than-expected quarterly loss of $1.06 per share. Despite insider selling, analysts maintain a "Moderate Buy" rating with an average price target of $137.33 for the stock.
Mirum Pharmaceuticals (MIRM) Losses Put Its Valuation Narrative Back In Focus
Mirum Pharmaceuticals (MIRM) reported wider net losses in Q2 and H1 2026, yet its share price has seen significant gains, up 28.91% year-to-date and 50.93% over one year. The company is currently trading at approximately $100, which analysts suggest is 30.2% undervalued with a consensus price target of $144.15, based on expectations of rapid revenue expansion and future profitability. However, risks like reimbursement decisions for Livmarli and trial results for VISTAS could alter this narrative.
Will Mirum Pharmaceuticals' (MIRM) Widening Net Losses Test Its Growth-Focused Investment Narrative?
Mirum Pharmaceuticals (MIRM) reported widening net losses for Q2 and H1 2026, with a six-month net loss of US$857.38 million, intensifying focus on cash burn and funding risks. Despite promising late-stage assets and catalysts like a potential FDA approval for zilurgisertib, investors are evaluating whether rising R&D and SG&A costs will be offset by future revenues. Analysts project significant revenue and earnings by 2029, but the substantial losses highlight the company's high-investment, growth-focused narrative.
Will Mirum Pharmaceuticals' (MIRM) Widening Net Losses Test Its Growth-Focused Investment Narrative?
Mirum Pharmaceuticals reported a significant net loss for Q2 and H1 2026, with basic loss per share rising, which highlights increased costs relative to revenue. This widening loss intensifies focus on cash burn and funding risks, despite upcoming clinical and regulatory catalysts such as the FDA's Priority Review for zilurgisertib. Investors will need to assess whether the company's promising late-stage assets can offset rising R&D and SG&A expenses, especially given prior shareholder dilution.
Wall Street Zen Downgrades Mirum Pharmaceuticals (NASDAQ:MIRM) to Sell
Wall Street Zen has downgraded Mirum Pharmaceuticals (NASDAQ:MIRM) from "hold" to "sell," despite the company reporting better-than-expected quarterly revenue of $176.24 million, a 37.9% increase year-over-year. The downgrade comes as the company missed earnings per share estimates, reporting a loss of $1.06 against a consensus of $0.74, and recent insider sales amounted to approximately $9.8 million. Despite the downgrade, the broader analyst consensus remains a "Moderate Buy" with a target price of $137.33.
Mirum Pharmaceuticals (MIRM) Stock Looks Fairly Valued After Recent News
Mirum Pharmaceuticals (MIRM) stock is currently considered fairly valued despite significant share price gains over the past five years. The company's P/S ratio of 10.4x is below the biotech industry average, suggesting it might still be on the inexpensive side. The future performance of the stock hinges on the continued revenue growth from LIVMARLI and progress in its broader pipeline.
Janus Henderson Group (MIRM) reports 5.9M Mirum Pharma shares under management
Janus Henderson Group Ltd., through its asset management subsidiaries, reported beneficial ownership of 5,909,184 shares of Mirum Pharmaceuticals, Inc. common stock, representing 9.7% of the class as of June 30, 2026. These shares are managed in client accounts (Managed Portfolios) where Janus Henderson holds shared voting and dispositive power, but the economic rights (dividends and sale proceeds) belong to the Managed Portfolios, with no single portfolio owning more than 5%. The filing clarifies that this ownership reflects aggregate holdings and is not intended to influence company control.
